Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Conduit Pharmaceuticals
Conduit Pharmaceuticals to Revolutionize Drug Development Through Agreement to Use Artificial Intelligence and Cybernetics
December 12, 2024
From
Conduit Pharmaceuticals
Via
GlobeNewswire
Tickers
CDT
Conduit Pharmaceuticals Receives Further Patent Approval For Lead Asset Targeting Autoimmune Disorders
November 21, 2024
From
Conduit Pharmaceuticals
Via
GlobeNewswire
Tickers
CDT
Conduit Pharmaceuticals Announces Appointment of Simon Fry to Board of Directors
November 19, 2024
From
Conduit Pharmaceuticals
Via
GlobeNewswire
Tickers
CDT
Conduit Pharmaceuticals Announces New Addition to its Autoimmune Pipeline
November 04, 2024
From
Conduit Pharmaceuticals
Via
GlobeNewswire
Tickers
CDT
Conduit Pharmaceuticals Announces Debt Restructuring and Additional Notes
November 01, 2024
From
Conduit Pharmaceuticals
Via
GlobeNewswire
Tickers
CDT
Conduit Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
August 28, 2024
From
Conduit Pharmaceuticals
Via
GlobeNewswire
Tickers
CDT
Conduit Pharmaceuticals Selects Initial Indications for Lead Clinical Candidate Targeting Autoimmune Disorders
August 12, 2024
From
Conduit Pharmaceuticals
Via
GlobeNewswire
Tickers
CDT
Conduit Pharmaceuticals Enters into Exclusive License Agreement with AstraZeneca for Multiple Assets to Advance Potential First-in-Class Treatments
August 08, 2024
From
Conduit Pharmaceuticals
Via
GlobeNewswire
Tickers
CDT
Conduit Pharmaceuticals Receives Patent Approval For Its Lead Asset Targeting Autoimmune Diseases
July 16, 2024
From
Conduit Pharmaceuticals
Via
GlobeNewswire
Tickers
CDT
Conduit Pharmaceuticals to Join Russell 3000® Index
June 13, 2024
From
Conduit Pharmaceuticals
Via
GlobeNewswire
Tickers
CDT
Conduit Pharmaceuticals Appoints Dr. Joanne Holland as Chief Scientific Officer
March 19, 2024
From
Conduit Pharmaceuticals
Via
GlobeNewswire
Tickers
CDT
Conduit Pharmaceuticals Announces Opening of Prime Laboratory Space in Europe’s Leading Life Sciences Hub
March 11, 2024
From
Conduit Pharmaceuticals
Via
GlobeNewswire
Tickers
CDT
Conduit Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
January 31, 2024
From
Conduit Pharmaceuticals
Via
GlobeNewswire
Tickers
CDT
Conduit Pharmaceuticals to Participate in the 14th Annual Jefferies London Healthcare Conference
November 02, 2023
From
Conduit Pharmaceuticals
Via
GlobeNewswire
Tickers
CDT
Conduit Pharmaceuticals Partners with ClinConnect on Cocrystal Development Program for AZD1656
October 11, 2023
From
Conduit Pharmaceuticals
Via
GlobeNewswire
Tickers
CDT
Conduit Pharmaceuticals and Murphy Canyon Acquisition Corp. Announce Completion of Business Combination
September 22, 2023
From
Conduit Pharmaceuticals
Via
GlobeNewswire
Tickers
CDT
MURF
SQFT
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.